Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Awatif Hafiz"'
Publikováno v:
Journal of Applied Hematology, Vol 15, Iss 1, Pp 82-85 (2024)
The most prevalent ticagrelor adverse effects are bleeding, dyspnea, bradycardia, and, in rare cases, thrombotic thrombocytopenic purpura. Although extremely rare, ticagrelor can cause absolute or profound thrombocytopenia. We present a case of total
Externí odkaz:
https://doaj.org/article/996ec589706e469e8f114cfba199d624
Autor:
Awatif Hafiz PharmD, BCCP, Hadeel Alkofide PhD, Khalid Al Sulaiman BCCCP, BCNSP, MBA, FCCM, Hala Joharji PharmD, BCPS, BCMTM, Sarah Aljohani PharmD, BCPS, Khadijah A. Sarkhi PharmD, Reem Alharbi PharmD, Ghazwa B. Korayem PharmD, BCPS, Mashael AlFaifi PharmD, BCPS, Samiah Alsohimi PharmD, Ohoud Aljuhani PharmD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
The prevalence of venous thromboembolism is high in patients with COVID-19, despite prophylactic anticoagulation. The evidence that supports the preferred thromboprophylaxis regimen in non-critically ill patients with mild to moderate COVID-19 is sti
Externí odkaz:
https://doaj.org/article/ef4a26e56ccb4240bf800fe922df2a42
Autor:
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Awatif Hafiz, Mai Alalawi, Hisham A. Badreldin, Ali F. Altebainawi, Ramesh Vishwakarma, Abdulrahman Alissa, Albandari Alghamdi, Abeer A. Alenazi, Huda Al Enazi, Shahad Alanazi, Abdullah Alhammad, Jahad Alghamdi, Mashael AlFaifi, Faisal A. Al Sehli, Maram A. Aldossari, Alaa A. Alhubaishi, Anfal Y. Al-Ali, Hasan M. Al-Dorzi
Publikováno v:
Thrombosis Journal, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background Thrombotic events are common in critically ill patients with COVID-19 and have been linked with COVID-19- induced hyperinflammatory state. In addition to anticoagulant effects, heparin and its derivatives have various anti-inflamm
Externí odkaz:
https://doaj.org/article/7767b9f73d1f4814aafcb7e17bec2b95
Autor:
Raed Kensara BSc.Pharm, SCC-CCP, BCPS, Ohoud Aljuhani PharmD, Ghazwa B Korayem PharmD, Hadeel Alkofide PhD, Sumaya N Almohareb PharmD, Yousef S Alosaimi PharmD, Ali F Altebainawi PharmD, Khalid Bin saleh PharmD, Norah Al Andas PharmD, MClinPharm, Shmeylan Al Harbi PharmD, Abdullah F Al Harthi PharmD, BCCCP, Uhood Ashkan PharmD, Rema Alghamdi PharmD, Hisham A Badreldin PharmD, Awatif Hafiz PharmD, Mashael AlFaifi PharmD, Rahaf A Alqahtani PharmD, Ramesh Vishwakarma PhD, Abeer A Alenazi PharmD, Mai Alalawi PharmD, Reem mahboob BSc.pharm, Renad A Alfouzan PharmD, Layan B Al Tuhayni PharmD, Nouf Al Qahtani BSc.pharm, MSc Med. Ed, Khalid Al Sulaiman BCCCP, BCNSP, MBA, FCCM
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 29 (2023)
Atrial fibrillation (Afib) can contribute to a significant increase in mortality and morbidity in critically ill patients. Thus, our study aims to investigate the incidence and clinical outcomes associated with the new-onset Afib in critically ill pa
Externí odkaz:
https://doaj.org/article/1ccd8ccd0378447f876bc769638f9f11
Autor:
Ohoud Aljuhani, Khalid Al Sulaiman, Awatif Hafiz, Khalid Eljaaly, Aisha Alharbi, Rahmah Algarni, Sarah Al Homaid, Khawla Kahtani, Tareq Alsulaiman, Ramesh Vishwakarma, Ghassan Al Ghamdi, Mai Alalawi, Ghazwa B. Korayem
Publikováno v:
Saudi Pharmaceutical Journal, Vol 30, Iss 4, Pp 398-406 (2022)
Introduction: The risk of mortality in patients with COVID-19 was found to be significantly higher in patients who experienced thromboembolic events. Thus, several guidelines recommend using prophylactic anticoagulants in all COVID-19 hospitalized pa
Externí odkaz:
https://doaj.org/article/c52d37f5761d4bb7ae8641891b094be1
Autor:
Shmeylan Al Harbi, Raed Kensara, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Abdullah Al Harthi, Ramesh Vishwakarma, Alaa M. Alenazi, Abdulmajed Almutairi, Omar Alshaya, Sultan Alraddadi, Tareq Al Sulaiman, Latifah Aldakkan, Reem Mahboob, Kholoud Alaamer, Abdulrahman Alissa, Awatif Hafiz, Nada Aldhayyan, Sara Althewaibi, Farhan Alenezi, Nadeen Y. Alkhotani, Sara A. Alghamdi, Abeer A. Alenazi, Khalid Al Sulaiman
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)
Purpose Coagulation abnormalities are one of the most important complications of severe COVID-19, which might lead to venous thromboembolism (VTE). Hypercoagulability with hyperfibrinogenemia causes large vessel thrombosis and major thromboembolic se
Externí odkaz:
https://doaj.org/article/3380178905e34bba9547df8771fb26cc
Autor:
Khalid Al Sulaiman SCC-CCP, BCCCP, BCNSP, MBA, Awatif Hafiz PharmD, BCCP, Hisham A. Badreldin PharmD, FCCP, BCPS, BCCP, Ghazwa B. Korayem PharmD, BCPS, Faisal Alsuwayyid PharmD, Abdulrahman Alrashidi, PharmD, Mohammed Alhijris PharmD, Faisal Almutairi, PharmD, Fahad Alharthi PharmD, Saad Alghamdi PharmD, Ahmed Abu Alreesh ClinPharmM.Sc, Ohoud Aljuhani PharmD, BCCCP
Publikováno v:
Journal of Investigative Medicine High Impact Case Reports, Vol 10 (2022)
Several guidelines endorsed the indefinite use warfarin or heparin-containing products for acute venous thromboembolism (VTE) treatment and secondary prevention and discouraged the use of direct oral anticoagulants (DOAC) for patients diagnosed with
Externí odkaz:
https://doaj.org/article/0cd5b2b17db149f7ba754f25f631240b
Publikováno v:
Thrombosis Update, Vol 5, Iss , Pp 100076- (2021)
Background: Both andexanet alfa and 4F-PCC reversal strategies have been associated with thrombotic events. It remains unclear whether the risk is associated with the reversal agent or the lack of re-initiation of anticoagulation. Objective: The aim
Externí odkaz:
https://doaj.org/article/32e0f2c793b840a1bdd6396d649c7638
Autor:
Hisham A. Badreldin, Nasser Aldosari, Lama Alnashwan, Taif Almutairi, Nada Yousif, Khalid Alsulaiman, Ohoud Aljuhani, Awatif Hafiz, Omar Alshaya
Publikováno v:
Journal of Cardiovascular Development and Disease, Vol 9, Iss 2, p 54 (2022)
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the P
Externí odkaz:
https://doaj.org/article/ad6ff78c12814ca9b3a704dc53f06aa8
Publikováno v:
Thrombosis Update, Vol 5, Iss, Pp 100076-(2021)
Background Both andexanet alfa and 4F-PCC reversal strategies have been associated with thrombotic events. It remains unclear whether the risk is associated with the reversal agent or the lack of re-initiation of anticoagulation. Objective The aim of